These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 28288645)

  • 1. Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells.
    He X; Wang L; Riedel H; Wang K; Yang Y; Dinu CZ; Rojanasakul Y
    Mol Cancer; 2017 Mar; 16(1):63. PubMed ID: 28288645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.
    Melaiu O; Stebbing J; Lombardo Y; Bracci E; Uehara N; Bonotti A; Cristaudo A; Foddis R; Mutti L; Barale R; Gemignani F; Giamas G; Landi S
    PLoS One; 2014; 9(1):e85935. PubMed ID: 24465798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.
    Servais EL; Colovos C; Rodriguez L; Bograd AJ; Nitadori J; Sima C; Rusch VW; Sadelain M; Adusumilli PS
    Clin Cancer Res; 2012 May; 18(9):2478-89. PubMed ID: 22371455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of mesothelin in carbon nanotube-induced carcinogenic transformation of human bronchial epithelial cells.
    He X; Despeaux E; Stueckle TA; Chi A; Castranova V; Dinu CZ; Wang L; Rojanasakul Y
    Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L538-49. PubMed ID: 27422997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
    Inaguma S; Wang Z; Lasota J; Onda M; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; OkoĊ„ K; Biernat W; Ikeda H; Schrump DS; Hassan R; Pastan I; Miettinen M
    Oncotarget; 2017 Apr; 8(16):26744-26754. PubMed ID: 28460459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter.
    Tan K; Kajino K; Momose S; Masaoka A; Sasahara K; Shiomi K; Izumi H; Abe M; Ohtsuji N; Wang T; Hino O; Fujii H
    Hum Pathol; 2010 Sep; 41(9):1330-8. PubMed ID: 20573372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesothelin promotes brain metastasis of non-small cell lung cancer by activating MET.
    Xia S; Duan W; Xu M; Li M; Tang M; Wei S; Lin M; Li E; Liu W; Wang Q
    J Exp Clin Cancer Res; 2024 Apr; 43(1):103. PubMed ID: 38570866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesothelin promotes the migration of endometrioid carcinoma and is associated with the MELF pattern.
    Tahara S; Nojima S; Takashima T; Okuzaki D; Morii E
    Pathol Res Pract; 2024 Oct; 262():155562. PubMed ID: 39182448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC/mesothelin expression.
    Kojima M; Kajino K; Momose S; Wali N; Hlaing MT; Han B; Yue L; Abe M; Fujii T; Ikeda K; Hino O
    Respir Res; 2020 Jul; 21(1):187. PubMed ID: 32677949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
    Hagemann UB; Ellingsen C; Schuhmacher J; Kristian A; Mobergslien A; Cruciani V; Wickstroem K; Schatz CA; Kneip C; Golfier S; Smeets R; Uran S; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Mumberg D; Ziegelbauer K; Cuthbertson AS
    Clin Cancer Res; 2019 Aug; 25(15):4723-4734. PubMed ID: 31064781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma.
    Kachala SS; Bograd AJ; Villena-Vargas J; Suzuki K; Servais EL; Kadota K; Chou J; Sima CS; Vertes E; Rusch VW; Travis WD; Sadelain M; Adusumilli PS
    Clin Cancer Res; 2014 Feb; 20(4):1020-8. PubMed ID: 24334761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A tumorigenic factor interactome connected through tumor suppressor microRNA-198 in human pancreatic cancer.
    Marin-Muller C; Li D; Bharadwaj U; Li M; Chen C; Hodges SE; Fisher WE; Mo Q; Hung MC; Yao Q
    Clin Cancer Res; 2013 Nov; 19(21):5901-13. PubMed ID: 23989979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model.
    Wang Y; Wang J; Yang X; Yang J; Lu P; Zhao L; Li B; Pan H; Jiang Z; Shen X; Liang Z; Liang Y; Zhu H
    Front Immunol; 2021; 12():628906. PubMed ID: 33777013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immuno-modulators enhance antigen-specific immunity and anti-tumor effects of mesothelin-specific chimeric DNA vaccine through promoting DC maturation.
    Chen YL; Chang MC; Chiang YC; Lin HW; Sun NY; Chen CA; Sun WZ; Cheng WF
    Cancer Lett; 2018 Jul; 425():152-163. PubMed ID: 29596890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of BRAF activated non-coding RNA is associated with poor prognosis for non-small cell lung cancer and promotes metastasis by affecting epithelial-mesenchymal transition.
    Sun M; Liu XH; Wang KM; Nie FQ; Kong R; Yang JS; Xia R; Xu TP; Jin FY; Liu ZJ; Chen JF; Zhang EB; De W; Wang ZX
    Mol Cancer; 2014 Mar; 13():68. PubMed ID: 24655544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma.
    Chu GJ; Linton A; Kao S; Klebe S; Adelstein S; Yeo D; Rasko JEJ; Cooper WA
    Histopathology; 2023 Aug; 83(2):202-210. PubMed ID: 37040900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy.
    Hager T; Borchert S; Wessolly M; Mathilakathu A; Mairinger E; Kollmeier J; Mairinger T; Hegedus B; Greimelmaier K; Wohlschlaeger J; Herrmann K; Mairinger FD
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.
    Awuah P; Bera TK; Folivi M; Chertov O; Pastan I
    Mol Cancer Ther; 2016 Jul; 15(7):1648-55. PubMed ID: 27196771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
    Adusumilli PS; Cherkassky L; Villena-Vargas J; Colovos C; Servais E; Plotkin J; Jones DR; Sadelain M
    Sci Transl Med; 2014 Nov; 6(261):261ra151. PubMed ID: 25378643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma.
    Kim MC; Hwang SH; Kim NY; Lee HS; Ji S; Yang Y; Kim Y
    BMC Cancer; 2018 Aug; 18(1):819. PubMed ID: 30111297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.